Today at #AACR26: @pashtoonkasi, medical director of GI oncology at @cityofhopeoc , will share breakthrough findings from the Clover Tria...

Back to meeting Original

Back to meeting

AACR 2026 现场信号· @ · X·2026-04-22 00:30· 2026-04-22Score60

#COLORECTALCANCER

Reading

KRAS / RAS 靶向 — 从平台化到 Ph3 验证

Deep dive

发生了什么

City of Hope的GI肿瘤医学总监Pashtoon Kasi将在AACR26会议上展示Clover试验的突破性发现，地点为Section 41、Poster 14，时间为下午2点至5点。

为什么重要

据报道该试验为II期研究^[1]，聚焦微卫星稳定型结直肠癌^[2]，并涉及一种靶向CCR5的Lironi MAP分子^[3]，这些数据可能为难治性结直肠癌提供新的治疗思路。

还缺什么

完整的疗效数据、安全性概况及生物标志物分析尚未公开，待会议墙报发布后进一步解读；后续需关注该试验是否推进至III期注册研究及监管沟通进展，目前均待确认。

References

1.Highlights from AACR 2026 Part 3 · oncodaily.com 2026
2.Pashtoon Kasi MD, MS · x.com 2026
3.#aacr26 #colorectalcancer | Pashtoon Kasi · linkedin.com 2026

Body · original

Today at #AACR26: @pashtoonkasi, medical director of GI oncology at @cityofhopeoc , will share breakthrough findings from the Clover Trial. Stop by Section 41, Poster 14, between 2 to 5 p.m. to learn more! #colorectalcancer

Heat 21 · 14 likes · 1 reply · 6 reposts

Source: AACR 2026 现场信号 · x.com